These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 26349824

  • 1. Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline.
    Honeyman L, Ismail M, Nelson ML, Bhatia B, Bowser TE, Chen J, Mechiche R, Ohemeng K, Verma AK, Cannon EP, Macone A, Tanaka SK, Levy S.
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7044-53. PubMed ID: 26349824
    [Abstract] [Full Text] [Related]

  • 2. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline.
    Macone AB, Caruso BK, Leahy RG, Donatelli J, Weir S, Draper MP, Tanaka SK, Levy SB.
    Antimicrob Agents Chemother; 2014 Nov; 58(2):1127-35. PubMed ID: 24295985
    [Abstract] [Full Text] [Related]

  • 3. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).
    Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT.
    Antimicrob Agents Chemother; 1999 Apr; 43(4):738-44. PubMed ID: 10103174
    [Abstract] [Full Text] [Related]

  • 4. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.
    Huband MD, Pfaller MA, Shortridge D, Flamm RK.
    J Glob Antimicrob Resist; 2019 Dec; 19():56-63. PubMed ID: 30825698
    [Abstract] [Full Text] [Related]

  • 5. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections.
    Villano S, Steenbergen J, Loh E.
    Future Microbiol; 2016 Oct; 11():1421-1434. PubMed ID: 27539442
    [Abstract] [Full Text] [Related]

  • 6. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines.
    Testa RT, Petersen PJ, Jacobus NV, Sum PE, Lee VJ, Tally FP.
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2270-7. PubMed ID: 8285606
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.
    Garrison MW, Nuemiller JJ.
    Int J Antimicrob Agents; 2007 Feb; 29(2):191-6. PubMed ID: 17174074
    [Abstract] [Full Text] [Related]

  • 9. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
    Zhanel GG, Esquivel J, Zelenitsky S, Lawrence CK, Adam HJ, Golden A, Hink R, Berry L, Schweizer F, Zhanel MA, Bay D, Lagacé-Wiens PRS, Walkty AJ, Lynch JP, Karlowsky JA.
    Drugs; 2020 Feb; 80(3):285-313. PubMed ID: 31970713
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH, Liu CY, Lu JJ, King CH, Hsueh PR.
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [Abstract] [Full Text] [Related]

  • 11. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ, Park CH.
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [Abstract] [Full Text] [Related]

  • 12. Recent developments in tetracycline antibiotics.
    Sum PE, Sum FW, Projan SJ.
    Curr Pharm Des; 1998 Apr; 4(2):119-32. PubMed ID: 10197036
    [Abstract] [Full Text] [Related]

  • 13. Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria.
    Jones RN, Wilson ML, Weinstein MP, Stilwell MG, Mendes RE.
    Diagn Microbiol Infect Dis; 2013 Apr; 75(4):402-5. PubMed ID: 23514756
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Surveillance on gram-positive bacteria isolated from patients with hospital acquired infections or community acquired infections].
    Li JT, Li Y, Wang J, China Bacterial Resistance Surveillance Study Group.
    Zhonghua Yi Xue Za Zhi; 2003 Mar 10; 83(5):365-74. PubMed ID: 12820911
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of the in vitro activity of tigecycline against multiresistant Gram-positive cocci containing tetracycline resistance determinants.
    Borbone S, Lupo A, Mezzatesta ML, Campanile F, Santagati M, Stefani S.
    Int J Antimicrob Agents; 2008 Mar 10; 31(3):209-15. PubMed ID: 17646087
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
    Farrell DJ, Castanheira M, Mendes RE, Sader HS, Jones RN.
    Clin Infect Dis; 2012 Sep 10; 55 Suppl 3():S206-14. PubMed ID: 22903953
    [Abstract] [Full Text] [Related]

  • 20. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ.
    Clin Ther; 2011 Dec 10; 33(12):1964-73. PubMed ID: 22078154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.